RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
tesmilifene
Class :
CYP3A4 Inhibitors, Antiplatelet agents
Brand Name :
N/A
Synonyms :
tesmilifene
Class :
CYP3A4 Inhibitors, Antiplatelet agents
Dosage forms and strengths:
This is used for research/investigation purpose
In vivo studies suggest this drugs act as adjuvant therapy for breast cancer
Not determined
Refer to the adult dosing regimen
Actions and spectrum:
Tesmilifene acts as a modulator of multidrug resistance (MDR), which potentially enhances the efficacy of chemotherapy.
Frequency not defined
Fatigue
Nausea
Weight gain
Skin rash
Erectile dysfunction
Headaches
Black box warning:
None
Contraindication/Caution:
The drug is contraindicated in following situations:
Hypersensitivity
Severe Liver Dysfunction
Pregnancy and breastfeeding
Pregnancy Warnings:
Pregnancy category: N/A
Lactation:
Excretion of the drug in human breast milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
<b>Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
The pharmacology of tesmilifene is associated with its role as a modulator of drug resistance.
Pharmacodynamics:
Tesmilifene is involved in overcoming resistance which enhances the sensitivity of cancer cells to chemotherapy.
Pharmacokinetics:
Limited information available on ADME.
Administration:
The route of administration is not fully known.
Patient information leaflet:
Generic Name: tesmilifene
Why do we use tesmilifene?
The drug has been studied for its role useful in management of breast cancer.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
